(Q34360714)

1 August 2017

title

Non-cystic fibrosis bronchiectasis. (English)

1 reference

1 August 2017

0 references

1 reference

Pamela J McShane

1

1 reference

1 August 2017

Edward T Naureckas

series ordinal

2

1 reference

1 August 2017

Gregory Tino

series ordinal

3

1 reference

1 August 2017

Mary E Strek

series ordinal

4

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2013

1 reference

American Journal of Respiratory and Critical Care Medicine

1 August 2017

published in

1 reference

1 August 2017

volume

188

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

647-656

1 reference

British Thoracic Society guideline for non-CF bronchiectasis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Analysis of the factors related to mortality in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Mortality in bronchiectasis: a long-term study assessing the factors influencing survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Reduction in bronchial subdivision in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Impaired tracheobronchial clearance in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Aetiology in adult patients with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Underlying host risk factors for nontuberculous mycobacterial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Bronchiectasis and nontuberculous mycobacterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Primary ciliary dyskinesia, an orphan disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Nitric oxide in primary ciliary dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Microbiologic follow-up study in adult bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Impact of human activities on the ecology of nontuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Biofilms: survival mechanisms of clinically relevant microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Molecular aspects of Moraxella catarrhalis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

21 January 2018

Staphylococcal biofilms

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Evolving concepts in biofilm infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Quorum sensing and social networking in the microbial world.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Effects of pulmonary rehabilitation in bronchiectasis: A retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Inhaled steroids in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Inhaled steroids improve quality of life in patients with steady-state bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Inhaled fluticasone in bronchiectasis: a 12 month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Use of inhaled corticosteroids and the risk of cataracts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

The use of antiinflammatory therapy and macrolides in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Exacerbations in cystic fibrosis: 4--Non-cystic fibrosis bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Risks associated with the therapeutic use of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Assessing response to treatment of exacerbations of bronchiectasis in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Thoracoscopic lobectomy for benign disease--a single centre study on 64 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Thoracoscopic lobectomy and segmentectomy for infectious lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Proton MRI appearance of cystic fibrosis: Comparison to CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

Sputum Candida albicans Presages FEV 1 Decline and Hospital-Treated Exacerbations in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0411CI

10.1164/RCCM.201303-0411CI

21 January 2018

Identifiers

DOI

1 reference

release_oizgvuck2jgxpddnf2s3nw27aa

1 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oizgvuck2jgxpddnf2s3nw27aa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference